BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

Much of the problem, from Szabo’s perspective, comes down to biomedicine placing greater emphasis (and incentives) on innovation rather than replication. As a result, “a lot of what is ...

Study a degree that sets you up to play your part in tackling cancer. You'll be taught by world renowned researchers at UCL working at the forefront of cancer research. Your skills and knowledge of ...

Inventiva (IVA) announced the publication in Biomedicine & Pharmacotherapy, a peer-reviewed, scientific journal, of the results from a preclinical study demonstrating that lanifibranor may reduce ...

Toon Overstijns, CEO, Miltenyi Biomedicine; Dr. Marinna Madrid, Co-Founder & Chief Product Officer, Cellino Biotec; Dr. K. Anand Kumar, Managing Director, Indian Immunologicals Limited; Sanjiv ...

Hyderabad: Miltenyi Biotec, a global leader in cell and gene therapy (CGT) solutions, has launched India's first dedicated Cell & Gene Therapy Center of Excellence (CoE) in Hyderabad. Located in ...

Dr Toon Overstijns, Managing Director of Miltenyi Biomedicine, called MITC a game-changer in accelerating breakthroughs in cell and gene therapies. Dr Boris Stoffel, chief commercial officer of ...

Miltenyi Biomedicine managing director and Miltenyi Biotec BV & Co KG board member Dr Toon Overstijns said, "MITC is a pivotal step in accelerating the global revolution in cell and gene therapies.